RC
BRNS

Rangeley Capital’s Barinthus Biotherapeutics BRNS Stock Holding History

Rangeley Capital’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$122K Buy
185,136
+25,671
+16% +$16.7K 0.11% 144
2026
Q1 		$90.7K Buy
159,465
+75,024
+89% +$49.4K 0.09% 120
2025
Q4 		$59.1K Buy
+84,441
New +$84.3K 0.05% 112

Other funds holding BRNS

MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
GP
GLR Partners Columbia, Maryland $215M AUM
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.5B AUM 13.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Rangeley Capital's BRNS Position: Q2 2026 in Review

Rangeley Capital increased its Barinthus Biotherapeutics (BRNS) stake by 16% in Q2 2026, buying an estimated $16.7K and bringing the position to 185,136 shares worth $122K. The position accounts for 0.11% of the portfolio, ranked #144.

Rangeley Capital first reported a position in BRNS in Q4 2025 and has held it in 3 quarters since. 15 funds tracked by Wall St. Rank hold BRNS as of Q2 2026.

  • Rangeley Capital held 185,136 shares of Barinthus Biotherapeutics worth $122K as of Q2 2026.
  • Rangeley Capital bought 25,671 Barinthus Biotherapeutics shares in Q2 2026, an estimated $16.7K.
  • Barinthus Biotherapeutics made up 0.11% of Rangeley Capital's portfolio in Q2 2026, its #144 holding.
  • Rangeley Capital first reported a position in Barinthus Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • 15 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q2 2026.

Based on Rangeley Capital's 13F filing for Q2 2026, filed 14 Aug 2026.